Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Glucose-dependent Insulinotropic Polypeptide (GIP) on Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
NCT05375968Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Feb 2023
- Primary completion
- May 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GIP(3-30)NH2 in postural orthostatic tachycardia syndrome (POTS) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Change in splanchnic venous capacitance in Postural Orthostatic Tachycardia Syndrome at 180 minutes, Effect of glucose-induced GIP secretion on splanchnic venous capacitance at 180 minutes and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
GIP(3-30)NH2
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT05375968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375968.